loader
Please Wait
Applying Filters...
menu
    • menu

    Digital Content for Avasopasem manganese

    Client Email Product
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Bora Pharmaceuticals- Making success more certain.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.

    Virtual Booth

    Contact Supplier

    Axplora- The partner of choice for complex APIs.

    Virtual Booth

    Contact Supplier

    Fareva is a one-stop-shop for API/HPAPI, OSD & Sterile products, is USFDA, EMA and PMDA-inspected and has multiple NDA & ANDA filings.

    Virtual Booth

    Contact Supplier

    Menu

    Avasopasem manganese

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PRICE INFORMATION

    DIGITAL CONTENT

    PharmaCompass
    $ API Ref.Price (USD/KG) : 181,907Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Galera tanks after FDA declines to approve avasopasem for patients with cancer
    Galera tanks after FDA declines to approve avasopasem for patients with cancer

    10 Aug 2023

    // REUTERS

    https://www.reuters.com/business/healthcare-pharmaceuticals/galera-shares-tank-after-us-fda-declines-approve-inflammation-disease-drug-2023-08-09/

    REUTERS
    10 Aug 2023
    Share Share
    Galera Announces Priority Review of Avasopasem NDA for Oral Mucositis
    Galera Announces Priority Review of Avasopasem NDA for Oral Mucositis

    15 Feb 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2023/02/15/2608650/0/en/Galera-Announces-FDA-Acceptance-and-Priority-Review-of-Avasopasem-NDA-for-Radiotherapy-Induced-Severe-Oral-Mucositis.html

    GLOBENEWSWIRE
    15 Feb 2023
    Share Share
    Galera Submits New Drug Application for Avasopasem for Severe Oral Mucositis
    Galera Submits New Drug Application for Avasopasem for Severe Oral Mucositis

    12 Dec 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2022/12/12/2571705/0/en/Galera-Submits-New-Drug-Application-for-Avasopasem-for-Severe-Oral-Mucositis.html

    GLOBENEWSWIRE
    12 Dec 2022
    Share Share
    Galera's Oral Presentation at 2022 ASCO on PIII ROMAN Trial of Avasopasem
    Galera's Oral Presentation at 2022 ASCO on PIII ROMAN Trial of Avasopasem

    26 May 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/05/26/2451643/0/en/Galera-Announces-Oral-Presentation-at-2022-American-Society-of-Clinical-Oncology-ASCO-Annual-Meeting-Detailing-Results-from-Phase-3-ROMAN-Trial-of-Avasopasem.html

    GLOBENEWSWIRE
    26 May 2022
    Share Share
    Galera shares rise over 100% as phase 3 flop deemed an error
    Galera shares rise over 100% as phase 3 flop deemed an error

    15 Dec 2021

    // A. Armstrong FIERCEBIOTECH

    https://www.fiercebiotech.com/biotech/turns-out-galera-s-radiotherapy-drug-did-work-after-all-and-investors-are-thrilled

    A. Armstrong FIERCEBIOTECH
    15 Dec 2021
    Share Share
    Galera shares slide as radiotherapy complication drug fails
    Galera shares slide as radiotherapy complication drug fails

    20 Oct 2021

    // A. Armstrong FIERCEBIOTECH

    https://www.fiercebiotech.com/biotech/galera-shares-slide-nearly-70-as-radiotherapy-complication-drug-flunks-out-phase-3

    A. Armstrong FIERCEBIOTECH
    20 Oct 2021
    Share Share